Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety

Carol A. Tamminga, Randall J. Mack, G. Richard Granneman, Christopher J. Silber, Kenneth B. Kashkin

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12-24 mg/day. Its action against positive symptoms is as potent as that of the traditional antipsychotic haloperidol. Its action against negative symptoms is significantly different from that of placebo and quantitatively larger than that of haloperidol. Its most distinctive characteristic is a reduction in motor side effects over a whole range of comparable drug and comparator doses. More work is needed to determine whether sertindole's actions against negative symptoms influence the primary or the secondary negative system. There are insufficient data at present to compare sertindole with the highly efficacious drug clozapine or the other new antipsychotic olanzapine.

Original languageEnglish (US)
Pages (from-to)S29-S35
JournalInternational Clinical Psychopharmacology
Volume12
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1997

Keywords

  • Akathisia
  • Antipsychotic
  • Haldol
  • Haloperidol
  • Negative symptoms
  • Parkinsonism
  • Psychosis
  • Schizophrenia
  • Serdolect
  • Sertindole

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety'. Together they form a unique fingerprint.

  • Cite this